Vaccine Financial News

Singapore has possibly peaked, and there is no need for additional measures, like wearing a face mask mandate, to be implemented, said Minister for Health (MOH) Ong Ye Kung. “We might have a slight surge, but I think more or less, we are seeing the peak of this wave," Channel News Asia quoted Ong as saying on Friday at the soft opening of a health campus at Woodlands in northern Singapore. However, having about 600 to 700 hospital beds taken up by COVID-19 patients is quite a strain on the system, the minister noted.

Christmas is a festival full of fun and frolic, vacations, entertainment, and all kinds of merry-making and meeting people. People across the world wait for this festival, but the Britishers have been advised to «avoid hugging» people this Christmas. They have also been asked to «wear masks» during this period while a 100-day cough makes its way around the country. After new figures revealed that whooping cough has seen an increase of 250% from last year, Virologist Professor Richard Tedder has advised the people. 'No hugging or kissing' rule

We don’t support this browser anymore. This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

COVID LIVE UPDATES A report by Moneycontrol mentioned that the Serum Institute of India (SII) currently offers a vaccine against the XBB1 variant of Covid-19, which is "similar" to the JN.1 variant. The spokesperson told the business website that SII would share the documents with the public once they are submitted to the regulators. Mint could not officially verify the report.

A sub-variant of the all-too-familiar Omicron, dubbed JN.1, is the villain this time around. India has experience combating mass covid infections, unlike when the pandemic hit us in 2020. Hospitals are better equipped with oxygen, ventilators and medical staff who know what to do in the face of a covid surge.

COVID-19 pandemic, Prime Minister Justin Trudeau says amid controversy surrounding government rapid test purchases.Trudeau faced questions stemming from a Global News investigation that found a rapid test importer landed an estimated $2 billion in federal contracts in 2021 and 2022, despite giving regulators incomplete data about its product’s accuracy.“During the pandemic, we were doing everything we could in unprecedented ways to get as many different ways of keeping Canadians safe as we possibly could, whether it was on rapid tests, whether it was on procurement of PPE, whether it was on contracts for vaccines, and getting the vaccines needed to make sure that Canadians got through this pandemic,” Trudeau told reporters in Toronto on Thursday.“There’s no doubt (there’s) lots of lessons to learn about things that worked really well, about things that we probably won’t be doing again in the next pandemic when it comes. But every step of the way through the pandemic, it was all hands-on deck with every different way we could do to try and make sure we were saving as many lives as possible, and getting our economy back on its feet as quickly as possible.”A year-long investigation into federal procurement revealed that BTNX, a small rapid test supplier based outside Toronto, deleted dozens of specimens, or samples, from a study it submitted to Health Canada.

here Experts attribute this volatility to profit booking amid rising Covid cases. They observe that the sudden spike in infections has instilled a cautious sentiment among investors, prompting them to reassess their positions and opt for profit-taking strategies amid this uncertain landscape. As Mint reported earlier, a new strain of Covid-19 has emerged in the country, raising fresh concerns.

JN.1 is a descendant of the "pirola" variant BA 2.86, which by itself is an Omicron subvariant. JN.1 has an additional mutation receptor binding domain (L455S) compared to BA 2.86. JN.1 has extensive resistance across receptor binding domain classes 1, 2, and 3 and shows higher immune evasion as compared with BA 2.86 and other resistant strains.

precautionary measures. The announcement about the increasing numbers of the new sub-variant, detected in three states, came with the Union Health Ministry reporting 614 new Covid infections, marking the highest daily count since May 21. As panic spread and Covid came under the spotlight again, experts stepped in to say there is no need to panic — available treatments are effective, the infection is mild and all viruses mutate.

₹30,000 loss per cattle as per National Disaster Response Force (NDRF) norms," Union minister for fisheries, animal husbandry and dairying Parshottam Rupala had said in a written reply to Lok Sabha in July this year. Over 115.7 million animals were also vaccinated against the LSD till July 2023, Rupala had said.

World Health Organization has classified the COVID-19 variant JN.1 as a separate variant of interest from the parent lineage BA.2.86 due to its rapidly increasing spread.The WHO made the announcement Tuesday, saying that based on current evidence, the global health risk posed by JN.1 remains low.“Despite this, with the onset of winter in the Northern Hemisphere, JN.1 could increase the burden of respiratory infections in many countries,” the WHO said in a statement.The health organization added it is continuously monitoring the evidence and will update the JN.1 risk evaluation as needed.Although JN.1 is now a variant of interest, the WHO said current vaccines continue to protect against severe disease and death in this variant, as others that are circulating.In Canada, JN.1 falls under the variant BA.2.86, which is an Omicron subvariant of SARS-CoV-2. Its prevalence has been steadily increasing since October, when it made up 0.1 per cent of the variants at the time.

Mint explains what the new virus is, its symptoms and efficacy of the vaccine: The new variant, experts have warned, appears to be more immune evasive and has been identified by WHO scientists as a ‘variant of interest’. JN.1 was first detected in the US in September 2023. By the end of October, it made up less than 0.1% of SARS-CoV-2 viruses, as per US Centers for Disease Control and Prevention (CDC).

coronavirus), with active cases rising to 1,828, as per the latest data from the Union Health Ministry on December 18. The death toll reached 5,33,317 according to the 8 am update. Further, India's total COVID-19 cases count stands at 4.50 crore (4,50,05,076).

NEW DELHI : The Union government has advised all states to implement tighter public health measures to minimise transmission of the Covid-19 virus, following a rise in infections in some states, particularly Kerala. The first case of a new sub-variant of Covid-19, JN.1, was detected on 8 December in the southern state, raising concerns about a resurgent health risk more than two years after India’s last pandemic-related lockdown.

Amid recent surge in coronavirus cases around the globe, India has detected a new variant of Covid-19 disease. The Ministry of health has confirmed that an infection linked to JN. 1 Covid strain was detected in Kerala on Sunday. The daily covid numbers also show a slight uptick across India. According to the health ministry’s official data, the daily caseload is nearing 2,000.

respiratory diseases and new JN.1 COVID sub-variant, the World Health Organisation (WHO) said that the virus is evolving and changing and urged the member states to continue with strong surveillance and sequence sharing. The global body also shared a video of its COVID-19 technical lead, Maria Van Kerkhove, who explained the reason for the recent surges and what precautions can be taken.

Niva Bupa Health Insurance Company, previously recognized as Max Bupa Health Insurance Company, has launched its newest offering, Aspire, with a specific focus on catering to the preferences and requirements of the Gen Z and millennial demographic. This product adopts a progressive approach to health insurance, aligning with the distinctive needs and aspirations of the younger generation.

Army Staff Gen Manoj Pande on Saturday said that India's «legacy challenges» of unsettled borders will continue to engage the nation and stressed that the ability to correctly assess future threats remains pivotal to the country's strategic planning and preparedness. The top general was delivering a keynote address at the Indian Institute of Management Nagpur, said a release shared by the defence PRO.

help prevent the spread of COVID-19, guidance that matches with what aerosol scientists say about preventing airborne diseases.“The other thing really is that if you’re sick, don’t go,” Gregson said.Dr. Lynora Saxinger, an infectious disease specialist at the University of Alberta Hospital, said there were lessons learned from the COVID-19 pandemic that can be used in a season of heightened influenza levels.“If you’re about to go into a social situation in a smaller, enclosed space with a whole bunch of people and some of them are quite elderly or have medical compromise, you might want to rethink the space and the time for that, or spread out the visits with smaller groups over a larger time, or at least pay some attention to ventilation,” she said.Like Gregson, Saxinger said someone starting to feel like they’re coming down with something should take a rain check on the visit.“If you are going to be visiting elderly people in long term care or something, because that’s when you do that, masking remains important and people often forget hand-washing actually really does help too,” she said.While the very old and the very young tend to have weaker immune systems that are more susceptible to severe outcomes from infections, Saxinger said the H1N1 family of influenza viruses is known to produce worse for younger populations.“I just checked the hospitalized flu case breakdown by age and indeed it has flipped.

At present, JN.1 constitutes a modest yet notable percentage, projected to potentially encompass 15-29% of circulating variants within the United States. While not yet widely spread in Europe, some countries have reported its presence at a slightly higher frequency, warranting cautious monitoring and analysis.

Moderna (NASDAQ:MRNA) shares rose more than 12% today after the company said its vaccine candidate, developed together with Merck (MRK) cuts the risk of skin cancer returning by nearly half.